Docosahexaenoic Acid, Folic Acid and Choline: study protocols
5 study groups took Docosahexaenoic Acid together with Folic Acid and Choline. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Docosahexaenoic Acid
5 study groups in 3 studies say how much Docosahexaenoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 60% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 0 |
| 1 g to 2.5 g | 3 |
Dose per serving from research: Folic Acid
5 study groups in 3 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mcg to 500 mcg, 60% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 3 |
| 500 mcg to 1 mg | 2 |
Dose per serving from research: Choline
5 study groups in 3 studies say how much Choline participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 60% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg or less | 1 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 3 |
| 500 mg to 1 g | 1 |
Commonly used together
5 of 5 study groups took Docosahexaenoic Acid, Folic Acid and Choline with something else, but nothing that 3 or more different studies gave.
5 study groups
| Study | |||||
|---|---|---|---|---|---|
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 930 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 600 mcg | 550 mg | 12 weeks | — |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1.2 g | 400 mcg | 400 mg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1.2 g | 400 mcg | 400 mg | 24 weeks | 201 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 400 mcg | 400 mg | 4 weeks | 16 |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 480 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 600 mcg | 100 mg | 12 weeks | — |